Pancreatic Cancer Research

ResearcherPeking University First HospitalActive in the last 2 years

Yinmo Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0000-3722-2457; OpenAlex author ID A5114626304. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41467-026-75772-5↗
  2. Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. Last author DOI 10.1136/gutjnl-2025-335683↗
  3. Multi-omics analysis of polyamine metabolism implicates NT5E/CD73 in the progression of pancreatic cancer. Last author DOI 10.1016/j.canlet.2025.217887↗
  4. Hypoxia-induced epigenetic regulation of miR-485-3p promotes stemness and chemoresistance in pancreatic ductal adenocarcinoma via SLC7A11-mediated ferroptosis. Last author DOI 10.1038/s41420-024-02035-x↗
  5. MicroRNAs as potential therapeutic targets for pancreatic cancer. Last author DOI 10.1097/cm9.0000000000001826↗
  6. A new nomogram for predicting lymph node positivity in pancreatic cancer. First author DOI 10.1016/j.hbpd.2020.12.022↗
  7. High mobility group AT-hook 2 promotes tumorigenicity of pancreatic cancer cells via upregulating ANLN. Last author DOI 10.1016/j.yexcr.2020.112088↗
  8. Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. Last author DOI 10.3892/or.2012.2210↗
  9. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. Last author DOI 10.1007/s10620-012-2036-4↗
  10. Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. Last author DOI 10.3892/or.2012.1808↗
  11. [Effects and mechanisms of combined suppression of epidermal growth factor receptor and hedgehog signaling on proliferation in pancreatic cancer cells]. Last author PMID 22944238↗
  12. [Regulatory mechanisms of Hedgehog signaling pathway for epithelial-mesenchymal transition in pancreatic cancer cells]. Last author PMID 22340649↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tian · 5 shared papers, 2021–2026 · strength 1.19
  2. Kai Chen · 3 shared papers, 2024–2026 · strength 0.73
  3. Yongsu Ma · 3 shared papers, 2024–2026 · strength 0.67
  4. Xiaodong Tian · 7 shared papers, 2011–2025 · strength 0.53
  5. Enkui Zhang · 2 shared papers, 2025–2026 · strength 0.47
  6. Xinxin Liu · 2 shared papers, 2024–2026 · strength 0.46
  7. Xiangyu Chu · 2 shared papers, 2022–2024 · strength 0.39
  8. Robert A. Anders · 1 shared paper, 2026 · strength 0.26
  9. Heng‐Chung Kung · 1 shared paper, 2026 · strength 0.26
  10. Pengfei Wu · 1 shared paper, 2026 · strength 0.26
  11. Jacquelyn W. Zimmerman · 1 shared paper, 2026 · strength 0.26
  12. Baoyi Li · 1 shared paper, 2025 · strength 0.20
  13. Mingzhe Li · 1 shared paper, 2025 · strength 0.20
  14. Yingjin Wang · 1 shared paper, 2025 · strength 0.20
  15. Dongqi Li · 1 shared paper, 2024 · strength 0.20
  16. Weikang Liu · 1 shared paper, 2024 · strength 0.20
  17. Chang-fu Qin · 5 shared papers, 2011–2013 · strength 0.19
  18. Kun Hao · 5 shared papers, 2011–2013 · strength 0.19
  19. Di Long · 1 shared paper, 2022 · strength 0.19
  20. Huahu Guo · 1 shared paper, 2020 · strength 0.13
  21. Yazhou Wang · 1 shared paper, 2020 · strength 0.13
  22. Zhigang Chang · 2 shared papers, 2011–2012 · strength 0.06
  23. Kun Xie · 2 shared papers, 2011–2012 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.